Welcome to Xention
Xention is developing novel therapies for the treatment of atrial fibrillation using its proprietary platform of ion channel drug discovery and development.
The Company is developing drug candidates that modulate two novel, but well characterised, ion channels and expects to develop breakthrough products in this area of huge unmet medical need.
In addition, we have established alliances with major pharmaceutical companies in areas outside our core interests.
XEN-D0103, a potent and selective Kv1.5 antagonist, is safe and well tolerated in healthy volunteers
XEN-D0103, a potent and selective Kv1.5 antagonist, commences single and multiple ascending dose study
Dr David Madge to present status of Xention Atrial Fibrillation research